CN1286531C - 抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 - Google Patents
抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 Download PDFInfo
- Publication number
- CN1286531C CN1286531C CN 200510013168 CN200510013168A CN1286531C CN 1286531 C CN1286531 C CN 1286531C CN 200510013168 CN200510013168 CN 200510013168 CN 200510013168 A CN200510013168 A CN 200510013168A CN 1286531 C CN1286531 C CN 1286531C
- Authority
- CN
- China
- Prior art keywords
- vegf
- abl2
- cell
- bcr3
- aso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
实验分组 | 浓度(nmol·L-1) | 细胞计数(×106) | 生长抑制率(%) |
ControlN-ODNASO-B3/A2ASO-VEGFASO-B3/A2+VEGF | 0200200200 | 4.38±0.204.33±0.103.79±0.183.82±0.122.56±0.42 | 01.1413.47a12.79b41.55c |
100+100 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510013168 CN1286531C (zh) | 2005-02-01 | 2005-02-01 | 抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510013168 CN1286531C (zh) | 2005-02-01 | 2005-02-01 | 抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679964A CN1679964A (zh) | 2005-10-12 |
CN1286531C true CN1286531C (zh) | 2006-11-29 |
Family
ID=35066951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510013168 Expired - Fee Related CN1286531C (zh) | 2005-02-01 | 2005-02-01 | 抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1286531C (zh) |
-
2005
- 2005-02-01 CN CN 200510013168 patent/CN1286531C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1679964A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sarkar et al. | Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells | |
Jiang et al. | Eradication of acute myeloid leukemia with FLT3 ligand–targeted miR-150 nanoparticles | |
Wang et al. | EGFR‐AS1 promotes bladder cancer progression by upregulating EGFR | |
Rizk et al. | The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk | |
Baradaran et al. | The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy | |
Qu et al. | Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use | |
WO2020030750A1 (en) | Microrna-based therapy targeted against lcp-1 positive cancers | |
Naiditch et al. | Mesenchymal change and drug resistance in neuroblastoma | |
CN101522898A (zh) | 使用Bcl-XL特异性siNA的癌症疗法 | |
CN1286531C (zh) | 抑制bcr3/abl2和VEGF基因功能的反义核酸药物组合物及其应用 | |
CN101036789A (zh) | 抗肿瘤的靶向粘附斑激酶fak的rna干扰药物 | |
CN1217700C (zh) | 抗肿瘤的多药耐药rna干扰药物 | |
CN105624325A (zh) | 肺腺癌的诊治标记物 | |
CN114601836B (zh) | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 | |
CN101445534A (zh) | 一种高效的siRNA在制备抑制肿瘤迁移药物中的用途 | |
CN103937801A (zh) | 多靶向siRNA分子及其抗肿瘤的应用 | |
CN112375823B (zh) | miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用 | |
CN103468799A (zh) | Eif5a2在制备食管鳞状细胞癌预后诊断试剂中的应用 | |
CN112522262B (zh) | 一种与胰腺癌相关的tRF及其应用 | |
CN102747083A (zh) | 剪切因子癌蛋白sf2/asf在制备白血病治疗药物中的应用 | |
CN105671195A (zh) | miR-520c核苷酸的用途、药物组合物和试剂盒 | |
Schito et al. | Metronomic chemotherapy offsets HIFo induction upon maximum-tolerated dose in metastatic cancers | |
CN1283802C (zh) | 一种新型重组腺病毒及其在恶性肿瘤治疗中的应用 | |
CN105586335A (zh) | 以miR-155前体为模板制备RNA探针的方法 | |
CN103937800A (zh) | 靶向多基因的siRNA分子及其抑制肿瘤的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tianjin AmCellGene Engineering Co., Ltd. Assignor: Taida Life Science and Technology Research Center, Hematology Inst., China Medic Contract record no.: 2011120000168 Denomination of invention: Antisense nucleic acid medicine composition for inhibiting function of bcr3/abl2 and VEGF gene and application thereof Granted publication date: 20061129 License type: Exclusive License Open date: 20051012 Record date: 20110825 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Tianjin AmCellGene Engineering Co., Ltd. Assignor: Taida Life Science and Technology Research Center, Hematology Inst., China Medic Contract record no.: 2011120000168 Date of cancellation: 20130513 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051012 Assignee: Guangzhou Han union Biological Technology Co., Ltd. Assignor: Taida Life Science and Technology Research Center, Hematology Inst., China Medic Contract record no.: 2013120000022 Denomination of invention: Antisense nucleic acid medicine composition for inhibiting function of bcr3/abl2 and VEGF gene and application thereof Granted publication date: 20061129 License type: Exclusive License Record date: 20130513 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061129 Termination date: 20190201 |